Uppsala, Sweden, 27 November 2020 – As Oasmia Pharmaceutical AB (”Oasmia”) has previously announced, the company’s current Chief Financial Officer (CFO), Michael af Winklerfelt, will leave his position on November 30, 2020 and Fredrik Järrsten will take over as permanent CFO in March 2021, at latest. To manage the transition, Oasmia today appointed Robert Maiorana as acting CFO, with effect from December 1, 2020.
Robert will hold the position until Fredrik Järrsten starts at Oasmia. Thereafter, Robert will work as finance manager in the company and in that role support Fredrik.
Since October 5, 2020, Robert has supported the company’s current CFO as a consultant. Robert’s consultancy assignment will be replaced with an employment contract from January 2021.
”I am glad Robert will be continuing with us at Oasmia,” said Francois Martelet, CEO of Oasmia. “Robert knows the company well and has already made significant contributions. Robert will bridge the period until Fredrik starts and once the handover is complete, Robert will assume a key role in our company as finance manager.”
Robert has extensive finance experience from senior positions. He has previously worked as finance and management consultant at Nacka Municipality and Bactiguard Holding AB and CFO at International Copyright Enterprise Services AB, ParaCell Solutions AB and MFEX Mutual Funds Exchange AB. He was also Head of Finance at Ryds Bilglas AB and ABN AMRO Bank Sweden. Robert holds a Bachelor of Science in Business and Economics from Lund University.
For more information:
Francois Martelet, Chief Executive Officer Oasmia
Phone: 018-50 54 40
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company’s proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com.